A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
Launched by HOFFMANN-LA ROCHE · May 13, 2011
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients, \>/= 18 years of age
- • Moderate to severe active rheumatoid arthritis (RA) of \>/= 6 months duration
- • Prior treatment with DMARDs for \>/= 12 weeks (at stable dose for \>/= 8 weeks)
- • Inadequate clinical response to stable dose of non-biologic DMARD (either single or in combination)
- Exclusion Criteria:
- • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment
- • Autoimmune disease other than RA
- • History of or current inflammatory joint disease other than RA
- • Previous treatment with any biologic drug that is used in the treatment of RA
- • Intra-articular or parenteral corticosteroids within 6 weeks prior to baseline
- • Impaired liver, renal or hematologic function
- • Active current or history of recurrent infection
- • History of or currently active primary or secondary immunodeficiency
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bandung, , Indonesia
Central Jakarta, , Indonesia
East Java, , Indonesia
Malang, , Indonesia
Yogyakarta, , Indonesia
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials